1 / 11

Featured Article :

Featured Article :. Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.

danno
Télécharger la présentation

Featured Article :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes Elisabeth R. Mathiesen, M.D., D.M.S.C., Moshe Hod, M.D., Marina Ivanisevic, M.D., Ph.D., Santiago Duran Garcia, M.D., Ph.D., Lise Brøndsted, Ph.D., Lois Jovanovič, M.D., Peter Damm, M.D., D.M.S.C., David R. McCance, M.D., On Behalf of the Detemir in Pregnancy Study Group Diabetes Care Volume 35: 2012-2017 October, 2012

  2. STUDY OBJECTIVE • Trial compared the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both with prandial insulin aspart) in pregnant women with type 1 diabetes Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  3. STUDY DESIGN AND METHODS • Patients randomized and exposed to IDet or NPH up to 12 months before pregnancy or at 8–12 weeks’ gestation • Noninferiority of IDet to NPH demonstrated with respect to A1C at 36 gestational weeks (GW) (margin of 0.4%) • Data analyzed using linear regression, taking several baseline factors and covariates into account Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  4. RESULTS • 310 type 1 diabetic women randomized and exposed to IDet (n = 152) or NPH (n = 158) up to 12 months before pregnancy (48%) or during pregnancy at 8–12 weeks (52%) • Estimated A1C at 36 GWs 6.27% for IDet and 6.33% for NPH in the full analysis set (FAS) • IDet declared noninferior to NPH (FAS, –0.06% [95% CI –0.21 to 0.08]; per protocol, –0.15% [–0.34 to 0.04]) • Fasting plasma glucose significantly lower with IDet versus NPH at both 24 GWs (96.8 vs. 113.8 mg/dL, P = 0.012) and 36 GWs (85.7 vs. 97.4 mg/dL, P = 0.017) • Major and minor hypoglycemia rates during pregnancy similar between groups Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  5. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  6. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  7. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  8. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  9. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  10. Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

  11. CONCLUSIONS • Treatment with IDet resulted in lower FPG and noninferior A1C in late pregnancy compared with NPH insulin • Rates of hypoglycemia were comparable Mathiesen E R et al. Diabetes Care 2012;35:2012-2017

More Related